

EURECCA ADJUVANT CHEMOTHERAPY AND RELATIVE SURVIVAL OF PATIENTS WITH STAGE II COLON CANCER

8-2-2016

OVERVIEW

1. Background & rationale

About 15% of patients with stage II colon cancer will develop metastatic disease within five years after diagnosis of the primary tumour. The aim of the present EURECCA international comparison is to compare both adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.

2. Research Questions

Are there differences in the proportion of adjuvant chemotherapy given between the countries?

Is there an association between different treatment strategies in countries with proportion of adjuvant chemotherapy and relative survival for patients with colon stage II who underwent surgery?

3. Methodology

Population-based national cohort data (2004-2009) and single-centre data from Lithuania (LT). Proportions of patients receiving adjuvant chemotherapy were calculated and compared between countries. Relative survival was calculated and compared between countries.

Klik hier om tekst in te voeren.

4. Study population

Patients with stage II colon cancer, who were surgically treated with curative intent, were included.
all ages
colon stage II
male and female

Dataset of 59,154 patients in total

5. Countries

Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), Belgium (BE), Lithuania (LT)

6. Progress

Conclusion of analysis The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. However, both SE and BE showed an improved adjusted relative survival compared with NL, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.

Submitted for publication EJC

WORK GROUP

Name	Function/registry	Country
Anne Breugom	PhD student, EURECCA	Netherlands
Esther Bastiaannet	Senior Epidemiologist, EURECCA	Netherlands
Petra Boelens	Surgeon, EURECCA	Netherlands
Lene Iversen	Surgeon, Danish Colorectal Cancer Group	Denmark
Lars Pahlman	Surgeon#, Swedish rectal cancer registry	Sweden
Anna Martling	Surgeon, Swedish Cancer Society	Sweden
T Evans	Public Health England Knowledge and Intelligence Team (West Midlands), Public Health England	UK
Katy O'Brien	National Cancer Registry Ireland	Ireland
Liesbeth van Eycken	Belgium Cancer Registry	Belgium
Rasa Janciauskiene	Medical Oncologist, Consultant of Lithuanian Health Ministry for Medical Oncology	Lithuania
GJ Liefers	Surgeon	Netherlands
Ton de Craen	Statisticus#	Netherlands
Andres Cervantes	Medical Oncologist	Spain
Valery Lemmens	Netherlands Comprehensive Cancer Organisation (IKNL)	Netherlands
Cornelis van de Velde	Surgeon, Dutch Surgical Colorectal Audit	Netherlands

#Lars Pahlman and Ton de Craen passed away the recent period.